DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

• Status: Completed
• Trial end date: 2004-11-01

Summary

The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.

• Phase: N/A

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Didanosine; Efavirenz; Lamivudine